Table 3 Targeted druggable genes from IHP and WGCNA networks in Mpox infection.

From: Exploration of drug repurposing for Mpox outbreaks targeting gene signatures and host-pathogen interactions

Gene

Signaling Pathway

Signaling Signature

Drug Effect/Drug Signature

Antiviral Drugs

IKKA

NF-κB/Act.

AV/AV

Inh/PV

-

HDAC1

WNT-β Cat./Inh.

PV/AV

Inh/PV

-

TF65 (RELA)

NF-κB/Act.

AV/AV

Inh/PV

-

HIPK2

Apoptosis (P53, CASP-8)/Act.

AV/AV

Inh/PV

-

PRKDC (DNA-PK)

IRF3 Signaling/Act.

AV/AV

Inh/PV

-

CDN1C

CDK & Cell Prolif./Inh.

PV/AV

Inh/PV

-

GSK3B

PI3K-Akt, WNT-β Cat., STAT3/Inh.

PV/AV

Act/AV

NIC, NIN, MID

ESR2 (ERβ)

PI3K-AKT, ERK-AP-1, STAT3/Inh.

PV/AV

Act/AV

EST, MPA, PROG, EE, SPIR, TAM, BIT, DES, RAL, FUL, E3, E1, LAS, BAZ, CTR

STAT3

STAT3 Signaling/Act.

PV/PV

Inh/AV

NIC, DIG, DIGT, OUA

AKT1

PI3K-Akt Signaling/Act.

PV/PV

Inh/AV

NIC, MIL

CDK4

PI3K-AKT, ERK-AP-1, STAT3/Act.

PV/PV

Inh/AV

ABE, CER, RIB, PAL, SUN

CSK21

Apoptosis, CASP-8/Inh.

AV/PV

Inh/AV

SUN, RUX, NIN

MK01 (ERK2)

MAPK-ERK1,2 Signaling/Act.

PV/PV

Inh/AV

TRE, TRO, ACE, SUL, DIC, MEC, ISO, BEN, BIT, MIF, ZAF, SOR

MK03 (MAPK3, ERK1)

MAPK-ERK1,2 Signaling/Act.

PV/PV

Inh/AV

HPC, DIS, TIO, CEL, NEL, HEX, MIF, ZAF, SOR, IMA

MK14 (MAPK14, p38)

AP-1 Signaling/Act.

PV/PV

Inh/AV

NEL, DES, ETO, AFA, MON, DAS, BIT, ISO, BEN, HEX, MIF, ZAF, SOR, NIL

MK08 (MAPK8, JNK1)

AP-1 Signaling/Act.

PV/PV

Inh/AV

AXI, NER, IMA, NIL, PAZ, RUX, MID, NIN

ARs

PI3K-Akt, MAPK-ERK1,2 Signaling/Act.

PV/PV

Act/PV

-

  1. Abbreviation list: ABE: abemaciclib; ACE: aceclofenac; Act: activator; AKT1: protein kinase B; ARs: androgen receptor; AV: antiviral; AXI: axitinib; BAZ: bazedoxifene; BEN: benzbromarone; BIT: bithionol; CDK4: cyclin-dependent kinase 4; CDN1C: cyclin-dependent kinase inhibitor; CEL: celecoxib; CER: ceritinib; CSK21: casein kinase 21; CTR: chlorotrianisene; DES: diethylstilbestrol; DIC: dicoumarol; DIG: digoxin; DIGT: digitoxin; DIS: disulfiram; E1: estrone; E3: estriol; EE: ethinylestradiol; ESR2 (ERβ): estrogen receptor beta; EST: estradiol; FUL: fulvestrant; GSK3B: glycogen synthase kinase 3 beta; HDAC1: histone deacetylase 1; HEX: hexachlorophene; HIPK2: apoptosis activator; HPC: hydroxyprogesterone caproate; IKKA: NF-κB activator; IMA: imatinib; Inh: inhibitor; ISO: isotretinoin; LAS: lasofoxifene; MEC: meclofenamic acid; MID: midostaurin; MID: midostaurin; MIF: mifepristone; miltefosine; MK01 (ERK2): extracellular signal-regulated kinase 2; MK03 (MAPK3: ERK1): extracellular signal-regulated kinase 1; MK08 (MAPK8: JNK1): c-Jun N-terminal kinase 1; MK14 (MAPK14: p38): mitogen-activated protein kinase 14; MIL: miltefosine; MPA: medroxyprogesterone acetate; NEL: nelfinavir; NER: neratinib; NIC: niclosamide; NIL: nilotinib; NIN: nintedanib; NIN: nintedanib; OUA: ouabain; PAL: palbociclib; PAZ: pazopanib; PRKDC (DNA-PK): IRF3 signaling activator; PROG: progesterone; PV: provirus; RAL: raloxifene; RIB: ribociclib; RUX: ruxolitinib; RUX: ruxolitinib; SOR: sorafenib; SPIR: spironolactone; STAT3: signal transducer and activator of transcription 3; SUL: sulfasalazine; SUN: sunitinib; TAM: tamoxifen; TF65 (RELA): NF-κB activator; TIO: tioguanine; TRE: tretinoin; TRO: troglitazone; ZAF: zafirlukast
Back to article page